Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Boldine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 known ✓ | P21728 | 5/20 | 0.98 |
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 0.98 |
| ▸ | CHRNA7 known ✓ | P36544 | 2/20 | 0.98 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.98 |
| ▸ | HTR2B known ✓ | P41595 | 4/20 | 0.87 |
| ▸ | HTR7 known ✓ | P34969 | 3/20 | 0.87 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.87 |
| ▸ | HTR5A known ✓ | P47898 | 1/20 | 0.87 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.87 |
| ▸ | HTR2A known ✓ | P28223 | 4/20 | 0.73 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.72 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.98 |
| ▸ | HPGD | P15428 | 7/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.98 |
| ▸ | MAPT | P10636 | 6/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Boldine SCHEMBL177549 | 0.99 | ALDH1A1 (1.00) | ALDH1A1HSD17B10HPGDKDM4EMAPT | |
| Boldine SCHEMBL13459203 | 0.99 | ALDH1A1 (1.00) | ALDH1A1HSD17B10HPGDKDM4EMAPT | |
| Boldine SCHEMBL29973042 | 0.99 | ALDH1A1 (1.00) | ALDH1A1HSD17B10HPGDKDM4EMAPT | |
| Boldine SCHEMBL177550 | 0.99 | ALDH1A1 (1.00) | ALDH1A1HSD17B10HPGDKDM4EMAPT | |
| Boldine SCHEMBL7387149 | 0.99 | ALDH1A1 (1.00) | ALDH1A1HSD17B10HPGDKDM4EMAPT | |
| Boldine SCHEMBL30184400 | 0.99 | ALDH1A1 (1.00) | ALDH1A1HSD17B10HPGDKDM4EMAPT | |
| Predicentrine SCHEMBL25844649 | 0.94 | ALDH1A1 (0.91) | ALDH1A1HSD17B10HPGDKDM4EMAPT | |
| Predicentrine SCHEMBL4410538 | 0.94 | ALDH1A1 (0.91) | ALDH1A1HSD17B10HPGDKDM4EMAPT | |
| Boldine SCHEMBL420488 | 0.93 | ALDH1A1 (0.89) | ALDH1A1HSD17B10HPGDKDM4EMAPT | |
| SCHEMBL4854015 | 0.93 | HTR7 (1.00) | ALDH1A1HSD17B10HPGDKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4716535-A2 | BOLDINE TO REDUCE MUSCLE ATROPHY AND PROMOTE NEUROMUSCULAR RECOVERY | The United States Government as represented by the Department of Veterans Affairs (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12246012-B2 | Method for treating nervous system injuries using boldine and derivatives thereof | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2025-03-11 | — | — | US | disclosed |
| WO-2024243339-A2 | BOLDINE TO REDUCE MUSCLE ATROPHY AND PROMOTE NEUROMUSCULAR RECOVERY | BURRELL JUSTIN (US) | 2024-11-28 | — | — | WO | disclosed |
| WO-2024167856-A1 | METHOD FOR TREATING NERVOUS SYSTEM DISORDERS USING BOLDINE AND ANALOGS THEREOF | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20230233548-A1 | Method for Treating Nervous System Injuries Using Boldine and Derivatives Thereof | US GOV VETERANS AFFAIRS (US) | 2023-07-27 | — | — | US | disclosed |
| US-11707459-B2 | Method for treating nervous system injuries using boldine and analogs thereof | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2023-07-25 | — | — | US | disclosed |
| US-8460642-B2 | Boldline compounds for promoting bone growth | OssiFi, Inc. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120301509-A1 | BOLDLINE COMPOUNDS FOR PROMOTING BONE GROWTH | OSTEOGENEX, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-8188065-B2 | Boldine compounds for promoting bone growth | OSTEOGENEX INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100092559-A1 | BOLDINE COMPOUNDS FOR PROMOTING BONE GROWTH | OSTEOGENEX INC. (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2010039920-A2 | BOLDINE COMPOUNDS FOR PROMOTING BONE GROWTH | OSTEOGENEX INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010026487-A1 | THERAPEUTIC METHODS AND COMPOSITIONS | UNIVERSITY OF CONCEPCION (CL) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092559-A1 | BOLDINE COMPOUNDS FOR PROMOTING BONE GROWTH | BMP2, BMP1, FGF23 | DRD1 2633/4885DRD2 2277/4885CHRNA7 4250/4885 |
| US-20120301509-A1 | BOLDLINE COMPOUNDS FOR PROMOTING BONE GROWTH | BMP2, BMP1, FGF23 | DRD1 2319/4885DRD2 2284/4885CHRNA7 2778/4885 |
| US-20230233548-A1 | Method for Treating Nervous System Injuries Using Boldine and Derivatives Thereof | ACHE, GAP43, SLC6A2 | DRD1 1021/4885DRD2 851/4885CHRNA7 50/4885 |
| US-12246012-B2 | Method for treating nervous system injuries using boldine and derivatives thereof | ACHE, GAP43, SLC6A2 | DRD1 1021/4885DRD2 851/4885CHRNA7 50/4885 |
| US-11707459-B2 | Method for treating nervous system injuries using boldine and analogs thereof | GAP43, ACHE, SLC6A2 | DRD1 1332/4885DRD2 1169/4885CHRNA7 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.